Kamran Mahmood

Positions:

Assistant Professor of Medicine

Medicine, Pulmonary, Allergy, and Critical Care Medicine
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.B.B.S. 1995

King Edward Medical University

M.P.H. 2005

University of Illinois

Resident, Internal Medicine

Nassau University Medical Center

Fellow, Pulmonary, Critical Care And Sleep Medicine

University of Illinois College of Medicine

Grants:

Lymphocyte exhaustion markers in malignanc pleural effusions of lung cancer

Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Role
Principal Investigator
Start Date
End Date

AminoIndex

Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Role
Principal Investigator
Start Date
End Date

Airflow 3: Multicenter randomized sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira Lung Denervation System in subjects with COPD

Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Role
Principal Investigator
Start Date
End Date

Lymphocyte Exhaustion Markers in Malignant Pleural Effusions of Lung Cancer

Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Role
Principal Investigator
Start Date
End Date

Publications:

Removal of Epithelialized Uncovered Metal Stent. A New Approach to An Old Problem.

Authors
MLA Citation
Cheng, George Z., et al. “Removal of Epithelialized Uncovered Metal Stent. A New Approach to An Old Problem.Annals of the American Thoracic Society, vol. 17, no. 5, May 2020, pp. 638–41. Epmc, doi:10.1513/annalsats.201909-722cc.
URI
https://scholars.duke.edu/individual/pub1439962
PMID
32356691
Source
epmc
Published In
Annals of the American Thoracic Society
Volume
17
Published Date
Start Page
638
End Page
641
DOI
10.1513/annalsats.201909-722cc

EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.

INTRODUCTION: Immune checkpoint pathway markers induce immune tolerance to non-small cell lung cancer (NSCLC). Therapeutic antibodies targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have demonstrated efficacy in tumors expressing relatively high PD-L1 levels. Minimally invasive endobronchial ultrasound-guided fine needle aspiration allows patients with inoperable tumors or comorbidities to attain a confirmatory diagnosis. The aims of the present study were to determine whether PD-L1 testing is equivalent to cytology and biopsy or resection specimens at different tumor proportion score cutoffs and for different NSCLC subtypes. MATERIALS AND METHODS: Data were retrospectively collected for patients with paired NSCLC cytology and surgical resection specimens from May 4, 2007 to May 4, 2017. The Food and Drug Administration-approved Dako PD-L1 immunohistochemistry 22C3 pharmDx kit was used to measure PD-L1 on paired cytology cell block and biopsy or resection specimens, and the PD-L1 tumor proportion scores were recorded. Statistical analysis of categorical and continuous variables was performed using SAS, version 9.4. RESULTS: A total of 53 paired cytology and resection samples (27 adenocarcinoma, 25 squamous cell carcinoma, and 1 unclassified) were analyzed. Supposing the resection specimen to reflect the true PD-L1 expression, the sensitivity, specificity, positive predictive value, negative predictive value, and overall agreement for the cytology method was 73.3%, 65.2%, 73.3%, 65.2%, and 69.8%, respectively. For high PD-L1 expression (≥50%), the cytology method demonstrated an overall agreement of 79.2%. The overall agreement between methods was 81.5% and 76% for cases of adenocarcinoma and squamous cell carcinoma, respectively. CONCLUSIONS: NSCLC cytology samples from endobronchial ultrasound-guided fine needle aspiration are suitable for PD-L1 testing, especially using a high PD-L1 expression cutoff of ≥50% and for adenocarcinoma.
Authors
Jug, R; Giovacchini, CX; Liu, B; Green, CL; Clarke, JM; Mahmood, K; Pavlisko, EN
MLA Citation
Jug, Rachel, et al. “EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.J Am Soc Cytopathol, Apr. 2020. Pubmed, doi:10.1016/j.jasc.2020.04.003.
URI
https://scholars.duke.edu/individual/pub1438217
PMID
32336671
Source
pubmed
Published In
J Am Soc Cytopathol
Published Date
DOI
10.1016/j.jasc.2020.04.003

American Association for Bronchology and Interventional Pulmonology (AABIP) Statement on the Use of Bronchoscopy and Respiratory Specimen Collection in Patients with Suspected or Confirmed COVID-19 Infection.

Authors
Wahidi, MM; Lamb, C; Murgu, S; Musani, A; Shojaee, S; Sachdeva, A; Maldonado, F; Mahmood, K; Kinsey, M; Sethi, S; Mahajan, A; Majid, A; Keyes, C; Alraiyes, AH; Sung, A; Hsia, D; Eapen, G
URI
https://scholars.duke.edu/individual/pub1435468
PMID
32195687
Source
pubmed
Published In
J Bronchology Interv Pulmonol
Published Date
DOI
10.1097/LBR.0000000000000681

Small Aperture Ultrasound Transducers for Intracavitary Tissue Ablation

© 2019 IEEE. Catheter directed ultrasound (US) transducer is capable of delivering high, focused acoustic power to the target tissue inside a body. The direct interaction with the tissue enables to minimize the concern of unintended tissue damages. Despite the potential advantages, the current therapeutic application of the intracavitary US device and literature is due to the inefficient delivery of the acoustic power from the small aperture and difficulty in fabrication. Therefore, we aim to develop a miniaturized intracavitary US transducer for tissue ablation. The proposed device is composed of double-layered PZT-5A, a matching layer, and a backing layer. Relatively high acoustic pressure (4.7 MPa) was generated by the small aperture (2 mm) prototypes. The therapeutic efficacy of the proposed method was validated through ex-vivo tests using porcine kidneys. Upon the sonification, the tissue temperature elevated to over 43 °C within 20 sec and the maximum temperature reached up to 53 °C at the five-minute sonification. The lesion volume after the US treatment was about 6.8 mm3. The developed catheter US transducer can be used to ablate a tumor in deep organs of the body by guiding it through an endoscopic device.
MLA Citation
Kim, H., et al. “Small Aperture Ultrasound Transducers for Intracavitary Tissue Ablation.” Ieee International Ultrasonics Symposium, Ius, vol. 2019-October, 2019, pp. 1842–45. Scopus, doi:10.1109/ULTSYM.2019.8925925.
URI
https://scholars.duke.edu/individual/pub1428584
Source
scopus
Published In
Ieee International Ultrasonics Symposium, Ius
Volume
2019-October
Published Date
Start Page
1842
End Page
1845
DOI
10.1109/ULTSYM.2019.8925925

Clinical and radiographic predictors of successful therapeutic bronchoscopy for the relief of malignant central airway obstruction.

BACKGROUND: Malignant central airway obstruction (CAO) occurs in approximately 20-30% of patients with lung cancer and is associated with debilitating symptoms and poor prognosis. Multimodality therapeutic bronchoscopy can relieve malignant CAO, though carries risk. Evidence to guide clinicians regarding which patients may benefit from such interventions is sparse. We aimed to assess the clinical and radiographic predictors associated with therapeutic bronchoscopy success in relieving malignant CAO. METHODS: We reviewed all cases of therapeutic bronchoscopy performed for malignant CAO at our institution from January 2010-February 2017. Therapeutic bronchoscopy success was defined as establishing airway patency of > 50%. Patient demographics and baseline characteristics, oncology history, degree of airway obstruction, procedural interventions, and complications were compared between successful and unsuccessful groups. Univariate and multivariate logistic regression identified the significant clinical and radiographic predictors for therapeutic success. The corresponding simple and conditional odds ratio were calculated. A time-to-event analysis with Kaplan-Meier plots was performed to estimate overall survival. RESULTS: During the study period, 301 therapeutic bronchoscopies were performed; 44 (14.6%) were considered unsuccessful. Factors associated with success included never vs current smoking status (OR 5.36, 95% CI:1.45-19.74, p = 0.010), patent distal airway on CT imaging (OR 15.11, 95% CI:2.98-45.83, p < 0.0001) and patent distal airway visualized during bronchoscopy (OR 10.77, 95% CI:3.63-31.95, p < 0.001) in univariate analysis. Along with patent distal airway on CT imaging, increased time from radiographic finding to therapeutic bronchoscopy was associated with lower odds of success in multivariate analysis (OR 0.96, 95% CI:0.92-1.00, p = 0.048). Median survival was longer in the successful group (10.2 months, 95% CI:4.8-20.2) compared to the unsuccessful group (6.1 months, 95% CI:2.1-10.8, log rank p = 0.015). CONCLUSIONS: Predictors associated with successful therapeutic bronchoscopy for malignant CAO include distal patent airway visualized on CT scan and during bronchoscopy. Odds of success are higher in non-smokers, and with decreased time from radiographic finding of CAO to intervention.
Authors
Giovacchini, CX; Kessler, ER; Merrick, CM; Gao, J; Wang, X; Wahidi, MM; Shofer, SL; Cheng, GZ; Mahmood, K
MLA Citation
Giovacchini, Coral X., et al. “Clinical and radiographic predictors of successful therapeutic bronchoscopy for the relief of malignant central airway obstruction.Bmc Pulm Med, vol. 19, no. 1, Nov. 2019, p. 219. Pubmed, doi:10.1186/s12890-019-0987-3.
URI
https://scholars.duke.edu/individual/pub1422331
PMID
31752776
Source
pubmed
Published In
Bmc Pulmonary Medicine
Volume
19
Published Date
Start Page
219
DOI
10.1186/s12890-019-0987-3